EP Patent

EP3808363A1 — Therapeutic agents for reducing parathyroid hormone levels

Assigned to Kai Pharmaceuticals Inc · Expires 2021-04-21 · 5y expired

What this patent protects

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X<sub>1</sub> - X<sub>2</sub> - X<sub>3</sub> - X<sub>4</sub> - X&…

USPTO Abstract

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X<sub>1</sub> - X<sub>2</sub> - X<sub>3</sub> - X<sub>4</sub> - X<sub>5</sub> - X<sub>6</sub> - X<sub>7</sub>, wherein the X<sub>1</sub> subunit comprises a thiol-containing moiety and the distribution of charge on the X<sub>2</sub>-X<sub>7</sub> subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP3808363A1
Jurisdiction
EP
Classification
Expires
2021-04-21
Drug substance claim
No
Drug product claim
No
Assignee
Kai Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.